title: Efficacy of ceftiofur hydrochloride for treatment of experimentally induced colibacillosis in neonatal swine.
abstract: Ceftiofur hydrochloride was tested for effectiveness against induced colibacillosis in neonatal swine. In this model, pigs less than 12 hours old were inoculated via stomach tube with a virulent, K99+, nalidixic acid-resistant strain of Escherichia coli. Six hours after challenge exposure, 1 dose of ceftiofur was administered either IM or orally in experiment 1 and orally only in experiment 2. Mortality, shedding of bacteria, fecal consistency scores, and body weight changes were monitored for 10 days. In experiment 1 (n = 383 pigs), all treatments at dosage that ranged between 0.5 and 64.0 mg of ceftiofur/kg of body weight significantly (P less than 0.001) reduced mortality, bacterial shedding, and diarrhea and increased weight gain, compared with findings in untreated controls. There were no detectable differences between oral and IM routes, except that there was greater reduction in bacteria shedding associated with the oral route of administration. In experiment 2 (n = 505 pigs), ceftiofur was administered orally either once at 6 hours after challenge exposure or twice at 6 and at 48 hours after the first dose. Dosage of ceftiofur was 0, 5, 10, 20, 30, or 60 mg/kg administered once, or half the same dose was administered at each of 2 times. At the optimal dosage (10 mg/kg), a single dose was as effective as 2 doses. The single administration at all dosages reduced mortality, bacterial shedding, and diarrhea scores and increased body weight gain, compared with findings in untreated pigs (P less than 0.01). In this induced infection model, the optimal treatment dosage was determined to be 10 mg/kg administered once.
authors.affiliation: Microbiology and Nutrition Research Unit, Upjohn Co., Kalamazoo, MI 49001.
authors.forename: R J
authors.initials: RJ
authors.lastname: Yancey
authors.forename: R A
authors.initials: RA
authors.lastname: Evans
authors.forename: D D
authors.initials: DD
authors.lastname: Kratzer
authors.forename: J B
authors.initials: JB
authors.lastname: Paulissen
authors.forename: S G
authors.initials: SG
authors.lastname: Carmer
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000831:Animals, Newborn; D002511:Cephalosporins / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D004927:Escherichia coli Infections / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*; D005243:Feces / Q000382:microbiology; D005260:Female; D007273:Injections, Intramuscular / Q000662:veterinary; D008297:Male; D013552:Swine; D013553:Swine Diseases / Q000188:drug therapy* / Q000209:etiology; D013997:Time Factors
chemical_list: D002511:Cephalosporins; C053503:ceftiofur